1
|
Ionova T, Andrievskikh M, Amdiev A, Baryakh E, Chang V, Endakova A, Fadeeva N, Husainova G, Ivanov V, Kaplanov K, Kaverina O, Kiseleva M, Klitochenko T, Kurakin V, Larionova O, Lazareva D, Lepik K, Lysenko I, Melnichenko V, Mikhailova N, Minullina R, Mironov O, Misyurina E, Mochkin N, Nikitina T, Osipov Y, Petrova T, Porfirieva N, Rukavitsyn O, Safin R, Samoylova A, Shelekhova T, Sherstnev D, Simashova P, Smirnova E, Trenina N, Vasiliev E, Volodicheva E. BRENTUXIMAB VEDOTIN FOR TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN A REAL WORLD SETTING: CLINICAL OUTCOMES AND IMPACT ON QUALITY OF LIFE. Hematol Oncol 2021. [DOI: 10.1002/hon.67_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- T. Ionova
- Multinational Center for Quality of Life Research Department of Hematology Saint Petersburg Russian Federation
| | - M. Andrievskikh
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine Hematology Chelyabinsk Russian Federation
| | - A. Amdiev
- V.M. Efetov Crimean Republican Oncology Center, Hematology Simferopol Russian Federation
| | - E. Baryakh
- City Clinical Hospital №52 Hematology Moscow Russian Federation
| | - V. Chang
- Tambov Regional Oncological Clinical Center Hematological Tambov Russian Federation
| | - A. Endakova
- Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency Hematological Kirov Russian Federation
| | - N. Fadeeva
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine Hematology Saint Petersburg Russian Federation
| | - G. Husainova
- Republican Clinical Oncology Center of the Ministry of Health of the Republic of Tatarstan, Hematological Kazan Russian Federation
| | - V. Ivanov
- Almazov National Medical Research Centre Department of Anesthesiology and Intensive Care Medicine Saint Petersburg Russian Federation
| | - K. Kaplanov
- S.P. Botkin City Clinical Hospital Hematological Department Moscow Russian Federation
| | - O. Kaverina
- Altai Regional Oncology Center Hematological Department Barnaul Russian Federation
| | - M. Kiseleva
- V.M. Efetov Crimean Republican Oncology Center, Hematology Simferopol Russian Federation
| | - T. Klitochenko
- Volgograd Regional Clinical Oncological Center Hematological Department Volgograd Russian Federation
| | - V. Kurakin
- Clinical Oncological Center, Hematological Department Omsk Russian Federation
| | - O. Larionova
- Primorskiy Regional Oncologic Center, Hematological Department Vladivostok Russian Federation
| | - D. Lazareva
- Altai Regional Oncology Center Hematological Department Barnaul Russian Federation
| | - K. Lepik
- RM Gorbacheva Research Institute of Pediatric Oncology Hematology and Transplantation, Pavlov University, Chemotherapy and Bone Marrow Transplantation Department Saint Petersburg Russian Federation
| | - I. Lysenko
- National Medical Research Centre for Oncology of the Ministry of Health of Russia, Department of Oncohematology Rostov‐on‐Don Russian Federation
| | - V. Melnichenko
- N.I. Pirogov National Medical Surgical Center Department of Hematology and Chemotherapy with a room of Bone Marrow and Hematopoietic Stem Cells Transplantation Moscow Russian Federation
| | - N. Mikhailova
- RM Gorbacheva Research Institute of Pediatric Oncology Hematology and Transplantation, Pavlov University, Chemotherapy and Bone Marrow Transplantation Department Saint Petersburg Russian Federation
| | - R. Minullina
- Republican Clinical Oncology Center of the Ministry of Health of the Republic of Tatarstan, Hematological Kazan Russian Federation
| | - O. Mironov
- Tambov Regional Oncological Clinical Center Hematological Tambov Russian Federation
| | - E. Misyurina
- City Clinical Hospital №52 Hematology Moscow Russian Federation
| | - N. Mochkin
- N.I. Pirogov National Medical Surgical Center Department of Hematology and Chemotherapy with a room of Bone Marrow and Hematopoietic Stem Cells Transplantation Moscow Russian Federation
| | - T. Nikitina
- Multinational Center for Quality of Life Research Department of Hematology Saint Petersburg Russian Federation
| | - Y. Osipov
- Almazov National Medical Research Centre Department of Oncohematology Saint Petersburg Russian Federation
| | - T. Petrova
- Republican Clinical Oncology Center of the Ministry of Health of the Republic of Tatarstan, Hematological Kazan Russian Federation
| | - N. Porfirieva
- Multinational Center for Quality of Life Research Department of Hematology Saint Petersburg Russian Federation
| | - O. Rukavitsyn
- N.N. Burdenko Main Military Clinical Hospital Hematological Center Moscow Russian Federation
| | - R. Safin
- Republican Clinical Oncology Center of the Ministry of Health of the Republic of Tatarstan, Hematological Kazan Russian Federation
| | - A. Samoylova
- N.I. Pirogov National Medical Surgical Center Department of Hematology and Chemotherapy with a room of Bone Marrow and Hematopoietic Stem Cells Transplantation Moscow Russian Federation
| | - T. Shelekhova
- Clinic of Professional Pathology and Hematology named after V.Ya. Shustov Saratov State Medical University Hematology Saratov Russian Federation
| | - D. Sherstnev
- Clinic of Professional Pathology and Hematology named after V.Ya. Shustov Saratov State Medical University Hematology Saratov Russian Federation
| | - P. Simashova
- N.N. Burdenko Main Military Clinical Hospital Hematological Center Moscow Russian Federation
| | - E. Smirnova
- N.I. Pirogov National Medical Surgical Center Department of Hematology and Chemotherapy with a room of Bone Marrow and Hematopoietic Stem Cells Transplantation Moscow Russian Federation
| | - N. Trenina
- Clinical Oncological Center, Hematological Department Omsk Russian Federation
| | - E. Vasiliev
- Regional Clinical Hospital Hematological Department Krasnoyarsk Russian Federation
| | - E. Volodicheva
- Tula Regional Clinical Hospital Hematological Department Tula Russian Federation
| |
Collapse
|
2
|
Ionova T, Anchukova L, Dubov S, Esenina T, Ivanova L, Kaplanov K, Kochkareva Y, Kopylova A, Kravchuk T, Levanov A, Li O, Nikitina T, Rukavitsyn O, Saraeva N, Savinova M, Shelekhova T, Simashova P, Shirokova M, Vinogradova O, Volkova S. 902P Quality of life and response to treatment with ixazomib-lenalidomide-dexamethasone (IRd) in patients with relapsed/refractory multiple myeloma (RRMM) in a real-world setting. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
3
|
Vinogradova J, Chumachenko A, Ryabchikova V, Kaplanov K, Ilyin N. IMMUNOCHEMORADIOTHERAPY OR IMMUNOCHEMOTHERAPY ONLY IN PATIENTS WITH EXTRANONAL DIFFUSE LARGE B-CELL LYMPHOMA OF STOMACH. Hematol Oncol 2019. [DOI: 10.1002/hon.127_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. Vinogradova
- Radiation and Combination Treatments; Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. Granov; St-Petersburg Russian Federation
| | - A. Chumachenko
- Radiation and Combination Treatments; Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. Granov; St-Petersburg Russian Federation
| | - V. Ryabchikova
- Radiation and Combination Treatments; Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. Granov; St-Petersburg Russian Federation
| | - K. Kaplanov
- Radiation and Combination Treatments; Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. Granov; St-Petersburg Russian Federation
| | - N. Ilyin
- Radiation and Combination Treatments; Russian Scientific Center for Radiology and Surgical Technologies named after Academician A.M. Granov; St-Petersburg Russian Federation
| |
Collapse
|
4
|
Stauder R, Eichhorst B, Hamaker ME, Kaplanov K, Morrison VA, Österborg A, Poddubnaya I, Woyach JA, Shanafelt T, Smolej L, Ysebaert L, Goede V. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol 2017; 28:218-227. [PMID: 27803007 DOI: 10.1093/annonc/mdw547] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Chronic lymphocytic leukemia (CLL) mainly affects older people: the median age at diagnosis is > 70 years. Elderly patients with CLL are heterogeneous with regard both to the biology of their disease and aging. Following the diagnosis of CLL in an elderly individual, careful risk assessment is essential when treatment options are evaluated. This includes not only clinical staging and evaluation of disease-specific prognostic biomarkers such as 17p deletion and TP53 mutation, but also of comorbidities, physical capacity, nutritional status, cognitive capacity, ability to perform activities of daily living and social support. Comorbidity scoring and geriatric assessment tools are helpful in achieving such multidimensional evaluation in a systematic manner. The introduction of new drugs including novel monoclonal antibodies and kinase inhibitors offers enhanced opportunities for the treatment of elderly patients with CLL. This position paper of a Task Force of the International Society of Geriatric Oncology (SIOG) reviews currently available evidence relevant to such patients. All types of elderly patient (i.e. chronological age > 65-70 years) are considered, from robust (fit) to vulnerable (unfit) to the terminally ill. Among the topics covered are the following: (i) the relationship between chronological age, prognosis and survival, (ii) assessment of biological aging, (iii) biological age as a determinant of treatment feasibility and tolerance and (iv) tailoring of both first and further-line treatment to the circumstances of the individual patient.
Collapse
Affiliation(s)
- R Stauder
- Department of Internal Medicine V (Hematology and Oncology), Innsbruck Medical University, Innsbruck, Austria
| | - B Eichhorst
- Department I of Internal Medicine, University Hospital Cologne, Center of Integrated Oncology (CIO) Cologne-Bonn, Cologne, Germany
| | - M E Hamaker
- Department of Geriatric Medicine, Diakonessenhuis, Utrecht, The Netherlands
| | - K Kaplanov
- Department of Hematology, Volgograd Regional Clinical Oncology Center, Volgograd, Russian Federation
| | - V A Morrison
- University of Minnesota, Hennepin County Medical Center, Minneapolis, USA
| | - A Österborg
- Karolinska University Hospital and Institute, Stockholm, Sweden
| | - I Poddubnaya
- Russian Medical Academy for Postgraduate Education, Moscow, Russian Federation
| | - J A Woyach
- Department of Internal Medicine, Ohio State University, Ohio, USA
| | - T Shanafelt
- Department of Hematology and Oncology, Mayo Clinic, Rochester, USA
| | - L Smolej
- 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic
| | - L Ysebaert
- Hematology Department, IUC Toulouse-Oncopole, Toulouse, France
| | - V Goede
- Department I of Internal Medicine, University Hospital Cologne, Center of Integrated Oncology (CIO) Cologne-Bonn, Cologne, Germany
| |
Collapse
|
5
|
Kaplanov K, Klitochenko T, Shipaeva A, Shirokova M, Matveeva I, Lavrishina N. Combination of idarubicin, vinblastine, dacarbazine, and gemcitabine (IVDG) as therapy for elderly patients with Hodgkin lymphoma with cardiac and pulmonary comorbidity. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_57] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- K. Kaplanov
- Hematology; Volgograd Regional Clinical Oncology Dispensary, Volgograd Medical Research Cente; Volgograd Russian Federation
| | - T. Klitochenko
- Hematology; Volgograd Regional Clinical Oncology Dispensary; Volgograd Russian Federation
| | - A. Shipaeva
- Hematology; Volgograd Regional Clinical Oncology Dispensary; Volgograd Russian Federation
| | - M. Shirokova
- Hematology; Volgograd Regional Clinical Oncology Dispensary; Volgograd Russian Federation
| | - I. Matveeva
- Hematology; Volgograd Regional Clinical Oncology Dispensary; Volgograd Russian Federation
| | - N. Lavrishina
- Hematology; Volgograd Regional Clinical Oncology Dispensary; Volgograd Russian Federation
| |
Collapse
|
6
|
Poddubnaya I, Babicheva L, Kaplanov K, Zaritskey A, Volodicheva E, Alexeev S, Loginov A, Orlova R, Dvornichenko V, Gladkov O, Kosinova M, Serduk O, Milovanov V, Myasnikov A, Suresh AV, Jain M, Patil S, Rajappa SJ, Ivanov R, Chernyaeva E. Comparison of pharmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e19545] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I. Poddubnaya
- Russian Medical Academy for Postgraduate Education, Oncology Department, Moscow, Russia
| | - L. Babicheva
- Russian Medical Academy for Postgraduate Education, Oncology Department, Moscow, Russia
| | - K. Kaplanov
- Volgograd Regional Clinical Oncological Dispensary, Volgograd, Russia
| | - Andrey Zaritskey
- Federal State Budgetary Institution “Federal Center of Heart, Blood and Endocrinology n.a. Almazov” of Ministry of Health of Russia, Saint Petersburg, Russia
| | | | - S. Alexeev
- Petrov Research Institute of Oncology, Saint Petersburg, Russia
| | - A. Loginov
- Haematology Centre at the Central City Hospital # 7, Yekaterinburg, Russia
| | - R. Orlova
- St. Petersburg Municipal Clinical Oncology Dispensary, Saint Petersburg, Russia
| | | | - Oleg Gladkov
- Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russia
| | - M. Kosinova
- Kemerovo Region Regional Clinical Hospital, Kemerovo, Russia
| | - O. Serduk
- Krasnodar Clinical Oncology Dispensary # 1, Krasnodar, Russia
| | - V. Milovanov
- Tambov Regional Clinical Oncology Dispensary, Tambov, Russia
| | - A. Myasnikov
- Republican Hospital named after V.A. Baranov, Petrozavodsk, Russia
| | | | | | - S. Patil
- Bangalore Institute of Oncology, Bangalore, India
| | | | | | | |
Collapse
|
7
|
Parovichnikova EN, Savchenko VG, Demidova IA, Isaev VG, Shuravina EN, Ustinova EN, Gribanova EO, Aleksanian MZ, Misiurin AV, Domracheva EV, Ol'shanskaia IV, Khoroshko ND, Kravchenko SK, Konstantinova TS, Anchukova LV, Kaplanov K, Zagoskina TP, Volkova SA, Filatov LB, Rekhtman GB, Sokolova I, Mashuk VN, Miliutina GI, Lapin VA, Perekatova TN, Sviridova EI, Pristupa AS, Ziuzgin IS. [Preliminary results of a multicenter randomized study on the treatment of acute promyelocytic leukemias]. TERAPEVT ARKH 2004; 76:11-8. [PMID: 15379121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
AIM To study efficacy of maintenance therapy of patients with acute promyelocytic leukemia (APL) in the APL treatment Russian multicenter trial. MATERIAL AND METHODS The trial was made with participation of 18 hematological departments of clinics in Russia. A total of 68 APL patients entered the trial. The maintenance therapy consisted of 5-day courses of cytostatic drugs which alternated or did not alternate with 5-day courses of ATRA. Cytogenetic tests were made in 31 patients, t(15;17) was detected in 26 of them. Molecular examination conducted in 28 patients discovered chimeric transcript PML/RARa in 26 of them. Of 20 patients examined in Hematological Research Center, 7 (35%) had a bcr 1/2 variant of the transcript PML/RARa, 13 (65%)--bcr 3 variant. RESULTS 65 patients were eligible for assessment. A complete remission was achieved in 90% cases. No resistance was observed. In follow-up within 30 months the recurrence rate was similar on both treatments. The results of the induction therapy and survival in patients with different variants of the transcripts were also similar. Overall 2.5 year survival for all the patients was 77%, recurrence-free--80%. The survival analysis in patients with leukocytosis higher and lower 10 x 10(9)/l found no statistical differences by the survival. Patients with hyperleukocytosis had higher early lethality than patients with leukocytes under 10 x 10(9)/l (25% vs 5.3%, p = 0.03). CONCLUSION The APL 06.01 protocol showed high efficacy of the relevant maintenance which provides a complete molecular remission in the majority of patients with probable recurrence-free 2.5 year survival 80%.
Collapse
|